Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib plus Erlotinib in Advanced NSCLC
NCT00265317Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2006
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Erlotinib + Sunitinib with Erlotinib + Placebo (2 arms). Primary endpoint: Progression-Free Survival. Started Jun 2006; status: completed.
02
Drugs
sunitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00265317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00265317.